MX2013013833A - COMPOSITIONS, USES AND METHODS FOR TREATMENT OF METABOLIC DISORDERS AND DISEASES. - Google Patents

COMPOSITIONS, USES AND METHODS FOR TREATMENT OF METABOLIC DISORDERS AND DISEASES.

Info

Publication number
MX2013013833A
MX2013013833A MX2013013833A MX2013013833A MX2013013833A MX 2013013833 A MX2013013833 A MX 2013013833A MX 2013013833 A MX2013013833 A MX 2013013833A MX 2013013833 A MX2013013833 A MX 2013013833A MX 2013013833 A MX2013013833 A MX 2013013833A
Authority
MX
Mexico
Prior art keywords
growth factor
fibroblast growth
treatment
methods
diseases
Prior art date
Application number
MX2013013833A
Other languages
English (en)
Other versions
MX349869B (es
Inventor
Lei Ling
Darrin A Lindhout
Original Assignee
Ngm Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201161504128P priority Critical
Priority to US201161515126P priority
Application filed by Ngm Biopharmaceuticals Inc filed Critical Ngm Biopharmaceuticals Inc
Priority to PCT/US2012/045087 priority patent/WO2013006486A2/en
Publication of MX2013013833A publication Critical patent/MX2013013833A/es
Publication of MX349869B publication Critical patent/MX349869B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/14Quaternary ammonium compounds, e.g. edrophonium, choline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factors [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose

Abstract

La invención se refiere a variantes y fusiones del factor 19 de crecimiento de fibroblasto (FGF19), variantes y fusiones del factor 21 de crecimiento de fibroblasto (FGF21), fusiones del factor 19 de crecimiento de fibroblasto (FGF19) y/o el factor 21 de crecimiento de fibroblasto (FGF21) y variantes o fusiones de proteínas del factor 19 de crecimiento de fibroblasto (FGF19) y/o el factor 21 de crecimiento de fibroblasto (FGF21), y las secuencias de péptidos (y peptidomiméticos), que tienen una o más actividades, tales como la actividad de reducción de la glucosa, y métodos para y usos en el tratamiento de hiperglicemia y otros trastornos.The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and / or factor 21 of fibroblast growth (FGF21) and protein variants or fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21), and the sequences of peptides (and peptidomimetics), which have a or more activities, such as glucose reduction activity, and methods for and uses in the treatment of hyperglycemia and other disorders.
MX2013013833A 2011-07-01 2012-06-29 COMPOSITIONS, USES AND METHODS FOR TREATMENT OF METABOLIC DISORDERS AND DISEASES. MX349869B (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US201161504128P true 2011-07-01 2011-07-01
US201161515126P true 2011-08-04 2011-08-04
PCT/US2012/045087 WO2013006486A2 (en) 2011-07-01 2012-06-29 Compositions, uses and methods for treatment of metabolic disorders and diseases

Publications (2)

Publication Number Publication Date
MX2013013833A true MX2013013833A (es) 2014-06-11
MX349869B MX349869B (es) 2017-08-17

Family

ID=47437648

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013833A MX349869B (es) 2011-07-01 2012-06-29 COMPOSITIONS, USES AND METHODS FOR TREATMENT OF METABOLIC DISORDERS AND DISEASES.

Country Status (27)

Country Link
US (7) US8951966B2 (es)
EP (2) EP2726511B1 (es)
JP (2) JP6254524B2 (es)
KR (1) KR102077721B1 (es)
CN (2) CN103649127A (es)
AU (1) AU2012279237B2 (es)
CA (1) CA2835607A1 (es)
CL (1) CL2013003416A1 (es)
CO (1) CO6940374A2 (es)
DK (1) DK2726511T3 (es)
ES (1) ES2748038T3 (es)
HK (1) HK1198297A1 (es)
HR (1) HRP20191713T1 (es)
HU (1) HUE045629T2 (es)
IL (1) IL274469D0 (es)
LT (1) LT2726511T (es)
MX (1) MX349869B (es)
MY (1) MY163674A (es)
NZ (1) NZ617746A (es)
PE (1) PE20141727A1 (es)
PL (1) PL2726511T3 (es)
PT (1) PT2726511T (es)
RU (1) RU2697762C2 (es)
SG (1) SG10201806648TA (es)
UA (1) UA118744C2 (es)
WO (1) WO2013006486A2 (es)
ZA (2) ZA201308421B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6016636B2 (ja) * 2009-10-15 2016-10-26 ジェネンテック, インコーポレイテッド Chimeric fibroblast growth factor with altered receptor specificity
AU2011239386B2 (en) 2010-04-16 2015-03-19 Salk Institute For Biological Studies Methods for treating metabolic disorders using FGF
PE20141727A1 (es) 2011-07-01 2014-11-26 Ngm Biopharmaceuticals Inc COMPOSITIONS, USES AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS AND DISEASES
US9475856B2 (en) * 2012-03-02 2016-10-25 New York University Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US9474785B2 (en) 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
US9464126B2 (en) 2012-06-07 2016-10-11 New York University Chimeric fibroblast growth factor 21 proteins and methods of use
US9283241B2 (en) * 2012-07-10 2016-03-15 Clemson University Treatment to render implants resistant to diabetes
CA2892152A1 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
EP2938740A4 (en) * 2012-12-27 2016-11-30 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9550820B2 (en) 2013-02-22 2017-01-24 New York University Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use
WO2014152993A1 (en) * 2013-03-14 2014-09-25 The Board Of Regents Of The University Of Oklahoma Use of klotho nucleic acids or proteins for treatment of diabetes and diabetes-related conditions
US20150104494A1 (en) * 2013-10-11 2015-04-16 Ohio State Innovation Foundation Methods for repair of ear canal tissue defects
WO2015061331A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
JP6621752B2 (ja) * 2013-10-21 2019-12-18 ソーク インスティテュート フォー バイオロジカル スタディーズ 変異した線維芽細胞増殖因子(fgf)1および使用方法
WO2015065897A1 (en) 2013-10-28 2015-05-07 Ngm Biopharmaceuticals, Inc. Cancer models and associated methods
PL3097122T3 (pl) 2014-01-24 2020-10-19 Ngm Biopharmaceuticals, Inc. 2 BETA KLOTHO DOMAIN BINDING ANTIBODIES AND THEIR APPLICATION
EP3104873B1 (en) * 2014-02-13 2019-09-04 Technische Universität München Fgf-8 for use in treating diseases or disorders of energy homeostasis
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
US10456449B2 (en) 2014-06-16 2019-10-29 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2016048995A2 (en) * 2014-09-23 2016-03-31 Salk Institute For Biological Studies Fgf19 truncations and mutants and uses thereof
KR20170075761A (ko) 2014-10-23 2017-07-03 엔지엠 바이오파마슈티컬스, 아이엔씨. 펩티드 변이체를 포함하는 약제학적 조성물 및 그의 사용 방법
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
EP3108893A1 (en) 2015-06-25 2016-12-28 Universite Claude Bernard - Lyon 1 Novel therapeutic use of fgf19
JP2018524005A (ja) * 2015-07-15 2018-08-30 プロージット ソウル バイオテクノロジー (ベイジン) カンパニー リミテッド Fusion polypeptides and methods of use
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
JP2018535964A (ja) 2015-10-30 2018-12-06 ソーク インスティテュート フォー バイオロジカル スタディーズ 線維芽細胞増殖因子(fgf)1アナログによるステロイド誘導性高血糖の処置
WO2017083276A1 (en) 2015-11-09 2017-05-18 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
US20190201490A1 (en) * 2016-05-25 2019-07-04 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of secretory disorders
CN107759696A (zh) * 2016-08-19 2018-03-06 安源医药科技(上海)有限公司 人白介素7融合蛋白及其制备方法
EP3630160A1 (en) * 2017-05-24 2020-04-08 Universitat Autònoma De Barcelona Viral expression construct comprising a fibroblast growth factor 21 (fgf21) coding sequence
KR102105623B1 (ko) 2017-11-22 2020-04-29 가천대학교 산학협력단 칼슘 및 포스파티딜이노시톨 포스페이트의 결합을 이용하여 질환 치료 후보물질을 스크리닝하는 방법
KR102054561B1 (ko) 2017-11-22 2019-12-10 가천대학교 산학협력단 C2 도메인 및 Akt 인산화 도메인 단편의 융합 단백질 및 이의 용도

Family Cites Families (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614396A (en) 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
CA2165162C (en) 1993-06-14 2000-05-23 Hermann Bujard Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5695977A (en) 1995-08-31 1997-12-09 Genetic Information Research Institute Site directed recombination
US7390879B2 (en) 1999-06-15 2008-06-24 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20060246540A1 (en) 1997-08-26 2006-11-02 Ashkenazi Avi J Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030113718A1 (en) 1997-09-17 2003-06-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2303834A1 (en) 1997-09-17 1999-03-25 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6767995B2 (en) 1997-09-17 2004-07-27 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030166051A1 (en) 1997-09-17 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2416538A1 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US7115415B2 (en) 2000-09-15 2006-10-03 Genentech, Inc. PRO9821 nucleic acids
US20030100497A1 (en) 2001-06-20 2003-05-29 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
DE69832539T2 (de) 1997-10-24 2006-07-20 Genentech, Inc., South San Francisco Polypeptid und dafür kodierendes Nukeinsäure
US20020042367A1 (en) 1997-11-25 2002-04-11 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US20020155543A1 (en) 1997-11-25 2002-10-24 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US20040126852A1 (en) 1997-11-25 2004-07-01 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
US20050026832A1 (en) 1997-11-25 2005-02-03 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
WO2000060085A1 (en) 1999-04-02 2000-10-12 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
US20020012961A1 (en) 1999-04-15 2002-01-31 Genentech, Inc. Fibroblast growth factor- 19
US20030211576A1 (en) 2000-02-22 2003-11-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7129072B1 (en) 1999-08-30 2006-10-31 New York University Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factor
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
WO2001018209A1 (en) 1999-09-10 2001-03-15 Curagen Corporation Fibroblast growth factor polypeptide and nucleic acids encoding same
US6797695B1 (en) 1999-10-22 2004-09-28 Kyoto University Human FGF-20 gene and gene expression products
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
JP2003516731A (ja) 1999-11-18 2003-05-20 カイロン コーポレイション ヒトfgf−21遺伝子および遺伝子発現産物
CA2396401A1 (en) 2000-01-05 2001-07-12 Zymogenetics, Inc. Novel fgf homolog zfgf12
WO2001049849A1 (en) 2000-01-05 2001-07-12 Zymogenetics, Inc. Novel fgf homolog zfgf11
US20010044525A1 (en) 2000-01-05 2001-11-22 Conklin Darrell C. Novel FGF Homolog zFGF12
US20020081663A1 (en) 2000-01-05 2002-06-27 Conklin Darrell C. Novel FGF homolog ZFGF11
US20060160181A1 (en) 2000-02-15 2006-07-20 Amgen Inc. Fibroblast Growth Factor-23 molecules and uses thereof
WO2001061007A2 (en) 2000-02-15 2001-08-23 Amgen, Inc. Fibroblast growth factor-23 molecules and uses thereof
EP1261638A2 (en) 2000-03-08 2002-12-04 Chiron Corporation Human fgf-23 gene and gene expression products
US20030105302A1 (en) 2000-03-08 2003-06-05 Nobuyuki Itoh Human FGF-23 gene and gene expression products
US20020001825A1 (en) 2000-03-31 2002-01-03 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
US20030065140A1 (en) 2000-04-03 2003-04-03 Vernet Corine A.M. Novel proteins and nucleic acids encoding same
JP2002112772A (ja) 2000-07-10 2002-04-16 Takeda Chem Ind Ltd 新規ポリペプチドおよびそのdna
EP2184296A1 (en) 2000-07-19 2010-05-12 Advanced Research And Technology Institute, Inc. Fibroblast growth factor (fgf23) and methods for use
US20070037165A1 (en) 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
IL139380D0 (en) 2000-10-31 2001-11-25 Prochon Biotech Ltd Active variants of fibroblast growth factor
WO2002041911A2 (en) 2000-11-22 2002-05-30 Bayer Corporation Use of fgf-19 for inhibiting angiogenesis
US20020151496A1 (en) 2000-12-08 2002-10-17 Bringmann Peter W. Novel fibroblast growth factors
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
DE10100588A1 (de) 2001-01-09 2002-07-18 Ribopharma Ag Verfahren zur Hemmung der Expression eines Zielgens
DE10100587C1 (de) 2001-01-09 2002-11-21 Ribopharma Ag Verfahren zur Hemmung der Expression eines Zielgens
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
AU2003225903A1 (en) 2002-03-21 2003-10-08 Curagen Corporation Methods of using farnesoid x receptor (fxr) agonists
US6987121B2 (en) 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
CA2486252C (en) 2002-06-07 2012-07-24 Genentech, Inc. Methods for screening for agents that modulate hepatocellular carcinoma development
CN101724071A (zh) 2004-10-08 2010-06-09 杜门蒂斯有限公司 抗肿瘤坏死因子受体1的单域抗体及其使用方法
US20050250684A1 (en) 2002-09-18 2005-11-10 Eli Lilly And Company Patent Division Method for reducing morbidity and mortality in critically ill patients
US20050181375A1 (en) 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
AT385806T (de) 2003-06-12 2008-03-15 Lilly Co Eli Fusionsproteine
US8609090B2 (en) * 2003-07-18 2013-12-17 Amgen Inc. Specific binding agents to hepatocyte growth factor
WO2005061712A1 (en) 2003-12-10 2005-07-07 Eli Lilly And Company Muteins of fibroblast growth factor 21
AU2005225513B2 (en) 2004-03-11 2012-01-12 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
DE602005016917D1 (de) 2004-05-13 2009-11-12 Lilly Co Eli Fgf-21-fusionsproteine
MXPA06014031A (es) 2004-06-01 2007-10-08 Domantis Ltd BISPECIFIC FUSION ANTIBODIES WITH IMPROVED SERICA MIDDLE LIFE.
JP2006016323A (ja) 2004-06-30 2006-01-19 Bio Integurensu:Kk Bioactive biomaterial
PT1789442E (pt) 2004-09-02 2009-11-11 Lilly Co Eli Muteínas do factor de crescimento de fibroblasto 21
US7622445B2 (en) 2004-09-02 2009-11-24 Eli Lilly And Company Muteins of fibroblast growth factor 21
WO2006049854A2 (en) 2004-10-29 2006-05-11 Genentech, Inc. Disruptions of genes encoding secreted proteins, compositions and methods relating thereto
AU2005300688B2 (en) 2004-11-03 2012-02-02 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
EP1831371A2 (en) 2004-12-14 2007-09-12 Eli Lilly And Company Muteins of fibroblast growth factor 21
UY29460A1 (es) 2005-04-08 2006-11-30 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
US7678890B2 (en) 2005-07-22 2010-03-16 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
CA2620082A1 (en) 2005-08-24 2007-03-01 Genizon Biosciences Inc. Genemap of the human genes associated with crohn's disease
EP1987055A1 (en) 2006-02-10 2008-11-05 Dermagen AB Novel antimicrobial peptides and use thereof
WO2007130673A2 (en) 2006-05-05 2007-11-15 Beth Israel Deaconess Medical Center Methods for the diagnosis and treatment of female infertility using molecular markers
WO2008021196A2 (en) 2006-08-09 2008-02-21 The Mclean Hospital Corporation Methods and compositions for the treatment of medical disorders
AU2007293465A1 (en) 2006-09-01 2008-03-13 American Type Culture Collection Compositions and methods for diagnosis and treatment of Type 2 Diabetes
AU2007315211B2 (en) 2006-11-03 2013-01-17 U3 Pharma Gmbh FGFR4 antibodies
CA2901105C (en) 2007-01-03 2018-02-13 California Stem Cell, Inc. Stem cell growth media and methods of making and using same
MX2009010531A (es) 2007-03-30 2009-11-26 Ambrx Inc MODIFIED FGF-21 POLYPEPTIDES AND USES OF THE SAME.
DK2550972T3 (en) 2007-04-02 2018-04-23 Genentech Inc otho-beta agonist antibody for use in the treatment of diabetes mellitus or insulin resistance
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
US20120142546A1 (en) 2007-12-10 2012-06-07 The Johns Hopkins University Hypomethylated genes in cancer
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
US20110195077A1 (en) 2010-01-29 2011-08-11 Novartis Ag Methods and compositions using fgf23 fusion ppolypeptides
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
US20090226459A1 (en) 2008-01-29 2009-09-10 Cold Spring Harbor Laboratory Role of fgf-19 in cancer diagnosis and treatment
NZ602702A (en) 2008-03-19 2014-03-28 Ambrx Inc Modified fgf-21 polypeptides and their uses
US20110015345A1 (en) 2008-03-19 2011-01-20 Ambrx, Inc. Modified FGF-23 Polypeptides and Their Uses
WO2009116861A2 (en) 2008-03-21 2009-09-24 Podiceps B.V. Diagnostic of pre-symptomatic metabolic syndrome
CN101591653B (zh) 2008-05-27 2013-07-31 中国人民解放军军事医学科学院野战输血研究所 低表达cyp7a1的肝细胞及其构建方法
US8034770B2 (en) 2008-06-04 2011-10-11 Amgen Inc. FGF21 polypeptides comprising two or more mutations
EP2300825A4 (en) 2008-06-18 2012-04-25 Abbott Lab P/gf-1 companion diagnostic methods and products
FR2933702A1 (fr) 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
WO2010006214A1 (en) 2008-07-09 2010-01-14 Ambrx, Inc. Fgf-21 neutralizing antibodies and their uses
BRPI0916904A2 (pt) 2008-08-04 2016-10-11 Fiveprime Therapeutics Inc polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos
EP2358749B1 (en) 2008-10-10 2018-07-18 Amgen, Inc Fgf21 mutants and uses thereof
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
EP2385826A4 (en) 2009-01-09 2012-04-04 Mayo Foundation Methods and materials for delivering bile acids
US20120035105A1 (en) 2009-01-09 2012-02-09 Sdg, Inc. Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
WO2010083051A2 (en) 2009-01-15 2010-07-22 ProChon Biotech, Ltd. Cartilage particle tissue mixtures optionally combined with a cancellous construct
HUE031840T2 (en) 2009-02-03 2017-08-28 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
SG10201707763PA (en) 2009-05-05 2017-11-29 Amgen Inc FGF21 Mutants And Uses Thereof
US8461111B2 (en) 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
US10241093B2 (en) 2009-05-28 2019-03-26 The Cleveland Clinic Foundation Trimethylamine-containing compounds for diagnosis and prediction of disease
US20120076729A1 (en) 2009-06-04 2012-03-29 Novartis Ag Methods of treating cancers
JP2012529463A (ja) 2009-06-11 2012-11-22 ノヴォ ノルディスク アー/エス 2型糖尿病を治療するための、glp−1とfgf21との組合せ
JP2013533227A (ja) 2010-06-08 2013-08-22 ノヴォ ノルディスク アー/エス Fgf21類似体および誘導体
US8324160B2 (en) 2009-06-17 2012-12-04 Amgen Inc. Chimeric polypeptides and uses thereof
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
JP6016636B2 (ja) 2009-10-15 2016-10-26 ジェネンテック, インコーポレイテッド Chimeric fibroblast growth factor with altered receptor specificity
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
CA2782420C (en) 2009-12-07 2017-11-14 Amgen Inc. Human antigen binding proteins that bind .beta.-klotho, fgf receptors and complexes thereof
WO2011084808A2 (en) * 2009-12-21 2011-07-14 Amunix Operating Inc. Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
EP2359843A1 (en) 2010-01-21 2011-08-24 Sanofi Pharmaceutical composition for treating a metabolic syndrome
EP3670534A3 (en) 2010-04-15 2020-09-09 Amgen Inc. Human fgf receptor and beta-klotho binding proteins
AU2011239386B2 (en) 2010-04-16 2015-03-19 Salk Institute For Biological Studies Methods for treating metabolic disorders using FGF
WO2012010553A1 (en) 2010-07-20 2012-01-26 Novo Nordisk A/S N-terminal modified fgf21 compounds
EP2613773A2 (en) 2010-09-09 2013-07-17 Trifoilium ApS Airway administration of angiogenesis inhibitors
EP2725034B1 (en) 2010-09-22 2019-04-03 Amgen Inc. Carrier immunoglobulins with no specificity for human tissues and uses thereof
CN102464712A (zh) 2010-11-11 2012-05-23 重庆富进生物医药有限公司 缺失型人成纤维细胞生长因子21变异体及其偶联物
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
JP5613547B2 (ja) 2010-12-14 2014-10-22 株式会社スクウェア・エニックス タスクベースの並列プログラミング言語
MX2013007327A (es) 2010-12-22 2014-01-08 Marcadia Biotech Inc METHODS TO TREAT METABOLIC DISORDERS AND OBESITY WITH ACTIVE GLUCAGON-BASED PEPTIDES FOR THE GIP AND GLP-1 RECEPTOR.
JP5850435B2 (ja) 2010-12-24 2016-02-03 国立研究開発法人産業技術総合研究所 ヒトfgf19活性の正確で高感度な測定方法ならびにヒトfgf19活性の制御剤
CN103533951B (zh) 2011-04-08 2017-04-19 安姆根有限公司 使用生长分化因子15(gdf‑15)治疗或改善代谢障碍的方法
WO2012140650A2 (en) 2011-04-12 2012-10-18 Hepacore Ltd. Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof
WO2012154263A1 (en) 2011-05-10 2012-11-15 Amgen Inc. Method of identifying compounds that specifically modulate the interaction of fgfr1 and beta-klotho
AU2012255881C1 (en) 2011-05-16 2015-11-26 Genentech, Inc. FGFR1 agonists and methods of use
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
AU2012267877B2 (en) 2011-06-08 2015-12-24 Denovo Biopharma (Hangzhou) Ltd. Co. Methods and compositions of predicting activity of retinoid X receptor modulator
WO2012177481A2 (en) 2011-06-24 2012-12-27 University Of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
PE20141727A1 (es) 2011-07-01 2014-11-26 Ngm Biopharmaceuticals Inc COMPOSITIONS, USES AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS AND DISEASES
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
WO2013027191A1 (en) 2011-08-25 2013-02-28 Novartis Ag Methods and compositions using fgf23 fusion polypeptides
AU2012301769B2 (en) 2011-08-31 2016-05-19 Amgen Inc. FGF21 for use in treating type 1 diabetes
TW201315742A (zh) 2011-09-26 2013-04-16 Novartis Ag 治療代謝病症之雙功能蛋白質
US9006400B2 (en) 2011-09-26 2015-04-14 Novartis Ag Fibroblast growth factor-21-Fc fusion proteins
AR087973A1 (es) 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos
CN103127503B (zh) 2011-11-23 2017-11-10 上海医学生命科学研究中心有限公司 拮抗和/或阻断IL‑6/IL‑6R/gp130信号通路在抗肝癌治疗中的用途
JP2015506944A (ja) 2012-01-18 2015-03-05 ジェネンテック, インコーポレイテッド Fgf19修飾薬を使用する方法
US9475856B2 (en) 2012-03-02 2016-10-25 New York University Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders
JP2013194049A (ja) 2012-03-23 2013-09-30 Kazuo Todokoro ヒト造血幹細胞を増幅させるための組成物及び方法
CA2868422A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of membrane proteins
EP2844273B1 (en) 2012-04-16 2018-01-31 Tel HaShomer Medical Research Infrastructure and Services Ltd. Klotho variant polypeptides and uses thereof in therapy
JP2015522539A (ja) 2012-05-15 2015-08-06 イーライ リリー アンド カンパニー 線維芽細胞増殖因子21タンパク質の治療目的の使用
US9474785B2 (en) 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
US9464126B2 (en) 2012-06-07 2016-10-11 New York University Chimeric fibroblast growth factor 21 proteins and methods of use
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子21蛋白質
MX2014015258A (es) 2012-06-11 2015-03-05 Lilly Co Eli VARIATIONS OF FIBROBLASTO GROWTH FACTOR 21.
RU2679130C2 (ru) 2012-07-11 2019-02-06 Блюпринт Медсинс Корпорейшн Ингибиторы рецептора фактора роста фибробластов
AR092076A1 (es) 2012-08-22 2015-03-18 Lilly Co Eli Proteinas homodimericas
PE20150648A1 (es) 2012-09-07 2015-05-25 Sanofi Sa Proteinas de fusion para el tratamiento de un sindrome metabolico
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
CA2892152A1 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
EP2938740A4 (en) 2012-12-27 2016-11-30 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9550820B2 (en) 2013-02-22 2017-01-24 New York University Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use
WO2014152090A1 (en) 2013-03-14 2014-09-25 Georgetown University Compositions and treatments of metabolic disorders using fgf binding protein 3 and fgf 19
WO2014152089A1 (en) 2013-03-14 2014-09-25 Georgetown University Compositions and treatments of metabolic disorders using fgf binding protein 3
WO2014149699A1 (en) 2013-03-15 2014-09-25 Eli Lilly And Company Bifunctional protein
JP6621752B2 (ja) 2013-10-21 2019-12-18 ソーク インスティテュート フォー バイオロジカル スタディーズ 変異した線維芽細胞増殖因子(fgf)1および使用方法
WO2015065897A1 (en) 2013-10-28 2015-05-07 Ngm Biopharmaceuticals, Inc. Cancer models and associated methods
PL3097122T3 (pl) 2014-01-24 2020-10-19 Ngm Biopharmaceuticals, Inc. 2 BETA KLOTHO DOMAIN BINDING ANTIBODIES AND THEIR APPLICATION
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
US10456449B2 (en) 2014-06-16 2019-10-29 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2016048995A2 (en) 2014-09-23 2016-03-31 Salk Institute For Biological Studies Fgf19 truncations and mutants and uses thereof
KR20170075761A (ko) 2014-10-23 2017-07-03 엔지엠 바이오파마슈티컬스, 아이엔씨. 펩티드 변이체를 포함하는 약제학적 조성물 및 그의 사용 방법
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2017083276A1 (en) 2015-11-09 2017-05-18 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
US20190194337A1 (en) 2016-08-26 2019-06-27 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
EP3503906A4 (en) 2016-08-29 2020-04-08 NGM Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders

Also Published As

Publication number Publication date
JP6634402B2 (ja) 2020-01-22
US9751924B2 (en) 2017-09-05
EP3597666A2 (en) 2020-01-22
RU2697762C2 (ru) 2019-08-20
CN103649127A (zh) 2014-03-19
EP2726511A2 (en) 2014-05-07
US20160168216A1 (en) 2016-06-16
CA2835607A1 (en) 2013-01-10
US9089525B1 (en) 2015-07-28
US9670260B2 (en) 2017-06-06
KR20140039322A (ko) 2014-04-01
DK2726511T3 (da) 2019-09-23
KR102077721B1 (ko) 2020-02-14
US10413590B2 (en) 2019-09-17
US9580483B2 (en) 2017-02-28
WO2013006486A3 (en) 2013-10-03
MY163674A (en) 2017-10-13
US8951966B2 (en) 2015-02-10
NZ617746A (en) 2016-07-29
EP2726511B1 (en) 2019-08-07
WO2013006486A2 (en) 2013-01-10
EP3597666A3 (en) 2020-04-22
US20130023474A1 (en) 2013-01-24
EP2726511A4 (en) 2015-12-02
US20170327551A1 (en) 2017-11-16
JP2017222651A (ja) 2017-12-21
JP2014527402A (ja) 2014-10-16
AU2012279237B2 (en) 2016-09-29
JP6254524B2 (ja) 2017-12-27
SG10201806648TA (en) 2018-09-27
ZA201308421B (en) 2016-01-27
HUE045629T2 (hu) 2020-01-28
PT2726511T (pt) 2019-10-14
LT2726511T (lt) 2019-11-11
US20160168215A1 (en) 2016-06-16
CL2013003416A1 (es) 2014-11-14
HRP20191713T1 (hr) 2019-12-27
CO6940374A2 (es) 2014-05-09
ZA201508231B (en) 2017-08-30
HK1198297A1 (zh) 2015-03-27
ES2748038T3 (es) 2020-03-12
CN105601748A (zh) 2016-05-25
AU2012279237A1 (en) 2013-05-16
PL2726511T3 (pl) 2019-12-31
RU2014103487A (ru) 2015-08-10
US20150284442A1 (en) 2015-10-08
WO2013006486A9 (en) 2013-08-15
PE20141727A1 (es) 2014-11-26
MX349869B (es) 2017-08-17
US20180355007A1 (en) 2018-12-13
IL274469D0 (en) 2020-06-30
UA118744C2 (uk) 2019-03-11

Similar Documents

Publication Publication Date Title
PH12015501806B1 (en) Novel benzopyran kinase modulators
MX2016006708A (es) BACTERIAL SYNERGIC COMPOSITIONS AND THEIR METHODS OF PRODUCTION AND USES.
PH12015500688A1 (en) Exendin-4 derivatives as dual glp1/glucagon agonists
MX2015011943A (es) RIBONUCLEIC ACIDS WITH NUCLEOTIDES MODIFIED BY 4'-UNCLE AND RELATED METHODS.
CR20140140A (es) Proteinas de fusión para el tratamiento de desordenes metabolicos
CR20130234A (es) Métodos de tratamiento de trastornos asociados con el fgf21
GT201500049A (es) Proteinas de fusiòn para el tratamiento de un sìndrome metàbolico
MX2015011769A (es) COMPOUNDS AND THEIR USES TO MODULATE HEMOGLOBIN.
PH12014500519B1 (en) Humanized anti-factor d antibodies and uses thereof
WO2013084000A3 (en) Exosomes for delivery of biotherapeutics
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
MX2019008085A (es) ACTIVIN-ACTRII ANTAGONISTS AND USES TO TREAT BONE AND OTHER DISORDERS.
HRP20130772T1 (hr) Sastavi koji sadrže skupove supramolekularnog inzulina korisni za lijeäśenje dijabetesa
AU2018253580A1 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
NZ709683A (en) Anti-pdgfr-beta antibodies and uses thereof
MX362452B (es) TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) USING VIRUSES ASSOCIATED WITH ADENO (AAV) SFLT-1.
MX2013011726A (es) METHOD OF TREATMENT OR IMPROVEMENT OF METABOLIC DISORDERS USING THE GROWTH DIFFERENTIATION FACTOR 15 (GDF-15).
PH12015501470A1 (en) Compositions and methods for the control of nematodes and soil borne diseases
WO2014066487A3 (en) Methods for treating anemia
TN2012000249A1 (en) Pyrazine derivatives and their use in the treatment of neurological disorders
PH12014502141A1 (en) New indanyloxydihydrobenzofuranylacetic acid derivatives and their use as gpr40 receptor agonists
MX2015011509A (es) COMPOUNDS AND USES OF THESE FOR THE MODULATION OF HEMOGLOBIN.
RU2013156968A (ru) Чистящие композиции, содержащие варианты амулазы в соответствии с перечнем последовательностей
BR112013032720A2 (pt) "derivados de azetidinil fenil, piridil ou pirazinil carboxamida como inibidores de jak, composição e uso dos referidos derivados"

Legal Events

Date Code Title Description
FG Grant or registration